One of the main mechanisms of action of bortezomib in cancer cells is the inhibition of the NF-κB pathway by blocking the proteasome degradation of its negative regulator IkB with consequently reduced production of proinflammatory cytokines including TNF-α [105,106]. Here, NFKB1 is linked to cancer.